Skip to content

    QMS Medical Allied Services Limited

    QMSMEDI
    Healthcare·20 Aug 2025
    Management Summary

    QMS Medical Allied Services reported a strong Q1 FY26 with record revenue of ₹46.5 crores, a 53% YoY increase, driven by robust performance in both products and services. EBITDA and PAT also saw significant growth. The company's Q-Devices segment achieved ₹10 crores in revenue in Q1, exceeding its entire FY25 performance, and the services business, including the acquired Saarathi, showed substantial growth. Management acknowledged concerns regarding share price performance and committed to addressing them.

    Highlights

    5
    • Revenue clocked ₹46.5 crores, highest ever for Q1, representing a 53% increase compared to Q1 FY25.

    • EBITDA stood at ₹6.76 crores for Q1 FY26, up from ₹4.95 crores in Q1 FY25, marking a 36.56% YoY growth.

    • Profit after tax (PAT) was ₹3.15 crores, an increase from ₹2.4 crores in Q1 FY25, reflecting a 31.25% YoY growth.

    • The company's own brand Q-Devices achieved a revenue of ₹10 crores in Q1 FY26, exceeding its entire FY25 performance.

    • Post Saarathi acquisition, the combined services program revenue increased 1.5 times in just 2 years, indicating significant potential in the Indian market.

    Concerns

    2
    • Saarathi's profit margin was slightly less this quarter, with a profit of approximately ₹50 lakhs on ₹4.6 crores revenue.

    • An analyst noted the company's share price journey is downward and the number of shareholders has reduced, despite good performance.

    What Changed1

    vs Q2 FY26

    Guidance items5 → 3 (-2)

    Key financials

    Single quarter

    03 metrics
    1. 01Revenue₹46.5 Cr+53%YoY
    2. 02EBITDA₹6.76 Cr+36.6%YoY
    3. 03PAT₹3.15 Cr+31.3%YoY

    Segment breakdown

    • Services (including Saarathi)₹11 Cr18.0%
    • Products₹35.5 Cr58.1%
    • Q-Devices₹10 Cr16.4%
    • Saarathi₹4.6 Cr7.5%
    Donut· Share of Revenue

    Capital allocation

    1
    high confidence
    CategoryHeadline
    M&A

    Saarathi

    acquisition · Other · Consideration ₹NaN (cash)

    Guidance & targets

    3
    CategoryTargetPriority
    Revenue
    Q-Devices Revenue
    ₹25 crores
    High
    Revenue
    Services Revenue (QMS + Saarathi)
    at least ₹60 crores
    High
    Growth
    Services Model Growth
    50% every year
    High

    Saarathi stake acquisition (25%)

    by September end 2025
    Current25% of remaining 49% stake to be acquired by September end 2025
    TargetCompletion of 25% stake acquisition in Saarathi

    Why it matters

    This is a committed M&A action that will increase ownership and integration of a key growth driver.

    Yes, we have this one in September and one other plan is, 25% by the September end, as per our agreements with and another 24% by next by September end.

    How to verify

    capital_allocation.m_and_a[target='Saarathi'].status

    Risks & concerns

    2
    RiskSeverity

    Share price performance and shareholder reduction

    An analyst highlighted that despite good performance, the share price journey is downward and the number of shareholders has reduced. Management stated their responsibility is to deliver good performance and will try to incorporate suggestions.Analyst acknowledged

    medium

    Incomplete Board of Directors information on NSE website

    An analyst pointed out that some data, like Board of Directors, is not uploaded on the NSE website. Management committed to updating it immediately.Analyst acknowledged

    low

    Q&A highlights

    8

    “For quarter 1 FY '26, it is approximately, combining Saarathi, we have done around Rs. 11 crores in the services and this thing and the balance has come from the products.”

    Provides a clear breakdown of the company's revenue streams for the reported quarter.

    asked by Garvita Jain

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q1 FY26 Financial Performance

    QMS Medical Allied Services reported its highest-ever Q1 revenue of ₹46.5 crores, marking a substantial 53% year-on-year growth. This robust top-line performance translated into significant profit expansion, with EBITDA increasing by 36.56% to ₹6.76 crores and Profit After Tax (PAT) growing by 31.25% to ₹3.15 crores. These results indicate the company's effective strategy in capitalizing on India's pharma promotion sector potential.

    02

    Exceptional Growth in Q-Devices Segment

    The company's own brand, Q-Devices, demonstrated remarkable performance by achieving ₹10 crores in revenue during Q1 FY26 alone. This figure surpasses the entire revenue generated by Q-Devices in the previous fiscal year (FY25), highlighting accelerated market penetration and acceptance. The growth is attributed to the introduction of new products, increased brand awareness, and successful engagement with institutional clients in the B2B space.

    03

    Services Business Expansion and Saarathi Integration

    The services business, including the acquired Saarathi, contributed ₹11 crores to the Q1 FY26 revenue. Post-acquisition, the combined services program revenue has grown 1.5 times in just two years, solidifying QMS's leadership in the B2B pharma promotion sector. Saarathi, a pioneer in patient service programs, reported ₹4.6 crores in revenue and approximately ₹50 lakhs in profit for Q1 FY26. The company plans to acquire the remaining 49% stake in Saarathi in tranches by September 2026, valuing it at 7x EBITDA.

    04

    Strategic Focus on Pharma Promotion Market

    Management characterized the Indian pharma promotion market as a highly unregulated and fragmented sector, estimated to be worth ₹10,000-₹12,000 crores. QMS positions itself as one of the few players with a turnover exceeding ₹100 crores in this segment. The company is actively exploring new opportunities in non-pharma domains for its patient service programs and CAMs business, alongside pursuing inorganic growth opportunities in the B2B space.

    05

    Humrahi Program: A Key Contributor

    The Humrahi program, a patient service initiative, is provided free of charge to patients, with QMS acting as a paid facilitator and coordinator. This program operates on an 80% fixed and 20% variable fee structure and contributes approximately 6-7% of the company's total turnover. It underscores QMS's commitment to patient services while generating a stable revenue stream.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.